City of Hope Board of Governors Induction of Sam Francis

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
City of Hope Board of Governors Induction of Sam Francis Senev, Chairman and CEO of Global Private Funding, Inc.

BEVERLY HILLS, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- Global Private Funding, Inc. (Global), a private equity lender announced today the induction of their Chairman & CEO Sam Francis Senev by the City of Hope Board of Governors. Global specializes in economic development through localized projects that create jobs. Global's projects are often the focus of EB-5 foreign investments and include healthcare, hospitality, education and technology sectors.

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=21441

"We are very proud of this honor" said Hamlet Betsarghez, an investor of Global.

The City of Hope Board of Governors provides targeted funding for specific research to secure specific results. In 2003 & 2009, a grant enabled Dr. Michael Jensen and Dr. Andrew Raubitschek to prove their theory of reprogramming T-cells to attack glioblastoma, an aggressive form of brain cancer. The project is now headed by Dr. Stephen Forman.

In 2006, Dr. Hua Yu discovered that STAT3, a protein, that is dormant in normal cells, but active in cancer cells. By de-activating STAT3, Dr. Yu found that the tumor cells die and surrounding immune cells regain their ability to fight cancer. The Board of Governors grant enabled Dr. Yu to apply for and receive numerous major grants from the National Institute of Health, and others.

Currently for 2013, the Board of Governors grant matched a private grant from a board member to Dr John Yim who discovered a compound, Baicalein, which activates a protein that causes cancer cells to kill themselves. His therapy containing Baicalein can be combined with chemotherapy to shrink tumors even further, while perhaps lessening the toxicity of the chemotherapy. 

Now and into the future, (2013/2014), to support Dr. John Burnett who heads up HIV/AIDS Laboratory, a grant will secure QX100 Droplet Digital PCR System that measures the level of cancer markers and to test new therapeutics which may reduce the levels of those cancer cells. The system will also be used to develop new anti-cancer agents currently under investigation for Pancreatic Cancer, B-cell Lymphoma and T-cell Leukemia as well as HIV/AIDS. Dr Burnett is preparing a patent application for the new developments. 

Senev, who has invested in several breakthroughs and has himself received stem cell therapy, is an avid supporter of medical innovation. His medical investments and involvements range from IPAs, wellness centers, hospitals, long term care facilities to medical equipment. His scientific expertise combined with financial resources enhances the board's capabilities. Senev was nominated by Board of Governors member Robert Staats. 

"Being a member of the City of Hope Board of Governors is an honor only bestowed to those who are beacons and icons in their own industries and is ONLY by invitation" said Robert S. Marx, Chairman Emeritus of the Board of Governors. Mr. Marx added that the Board of Governors has to date granted over 30 million to support cancer research. 

City of Hope Mildred Marin Coordinator P: 800-544-3541 ext. 26375 Global Private Funding, Inc. 800-226-8146

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

FDA Greenlights Kisqali®: A Major Step for Breast Cancer Care

Updated Category News Views 203

Kisqali® Receives FDA Approval for Early Breast Cancer Treatment Novartis has some exciting news for oncology: the US Food and Drug Administration (FDA) has officially approved Kisqali® (ribociclib) as a treatment for patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer...

Continue Reading
Ålandsbanken Abp Launches SEK 350M Additional Tier 1 Notes Series

Updated Category News Views 162

Ålandsbanken Abp Issues SEK 350,000,000 Additional Tier 1 Notes Ålandsbanken Abp, a prominent player in the banking industry, recently made waves in the financial market by issuing Additional Tier 1 floating rate notes amounting to SEK 350,000,000. The issuance marks a significant step in Ålandsbanken's strategic move to strengthen its capital position and enhance its...

Continue Reading
Harbour BioMed's 2025 Achievements and Future Prospects

Updated Category News Views 249

Harbour BioMed Achieves Significant Milestones in Interim Results Harbour BioMed (HKEX: 02142) is a prominent biopharmaceutical company focused on developing innovative antibody therapeutics, particularly in the fields of immunology and oncology. The company shared its impressive interim results for the first half of the year, showcasing remarkable growth and strategic...

Continue Reading
Innovative Investment Fuels Okika Devices' Future Growth Strategy

Updated Category News Views 187

Strategic Investment Boosts Okika Devices Advancement Colorado ONE Fund, which is part of the ONE Funds initiative, has made a major investment in Okika Devices, a company recognized for its innovation in Field Programmable Analog Array (FPAA) technology. This investment aligns with Colorado ONE Fund's mission to support technologies that advance the local innovation...

Continue Reading
Investors Take Note: Legal Options for Shareholders Explored

Updated Category News Views 61

Exploring Legal Options for Investors in Major Companies In recent developments, Halper Sadeh LLC, a reputable law firm focusing on investor rights, is carefully examining three significant companies for potential violations of federal securities laws. This investigation centers around the actions and decisions made by these firms, which may affect shareholders' rights...

Continue Reading